Company Overview
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.22.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +76.57% |
| 6 Months: | +42.74% |
| 3 Months: | +19.78% |
| 1 Month: | +8.39% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)62.16 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PHVS Pharvaris N.V. PHARMA | 37.84 | -12.61 | $2.66B | 0.00% | -62.47% | -70.46% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 42.19M | 40.37M | 39.66M | 47.60M | 44.27M |
| Operating Income | - | -42.19M | -40.37M | -39.66M | -47.60M | -44.27M |
| EBITDA | - | -42.08M | -40.27M | -39.56M | -47.49M | -44.17M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -46.04M | -45.28M | -37.32M | -45.08M | -38.93M |
| Tax Provision | - | 302.67K | 202.78K | -181.47K | 1.66M | 273.11K |
| Net Income | - | -46.34M | -45.48M | -37.14M | -46.74M | -39.20M |
| Diluted EPS | - | -0.85 | -0.83 | -0.60 | - | -0.60 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 86.71M | 96.91M | 145.69M | 169.82M |
| Operating Income | - | -86.71M | -96.91M | -145.69M | -169.82M |
| EBITDA | - | -86.56M | -96.66M | -145.42M | -169.40M |
| Interest Expense | 267.51K | 16.11K | - | - | - |
| Pretax Income | - | -75.65M | -99.83M | -132.40M | -173.71M |
| Tax Provision | - | 679.09K | 1.05M | 1.83M | 1.99M |
| Net Income | - | -76.33M | -100.88M | -134.22M | -175.70M |
| Diluted EPS | - | -2.27 | -2.63 | -2.48 | -2.97 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 167.73M | 398.69M | 291.37M | 301.45M |
| Current Assets | - | 166.85M | 397.85M | 289.42M | 299.17M |
| Cash & Equivalents | - | 161.84M | 391.23M | 280.73M | 291.68M |
| Inventory | - | - | - | - | - |
| Receivables | 8.45K | 0 | - | - | - |
| Total Liabilities | - | 18.47M | 14.65M | 23.61M | 30.18M |
| Current Liabilities | - | 18.22M | 14.60M | 22.97M | 29.60M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 436.82K | 238.91K | 861.47K | 776.80K |
| Total Equity | - | 149.26M | 384.05M | 267.76M | 271.27M |
| Shares Outstanding | - | 33.82M | 52.29M | 54.38M | 65.21M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -67.16M | -93.05M | -120.13M | -137.07M |
| Investing Cash Flow | - | -124.30K | -89.98K | -538.09K | -164.62K |
| Financing Cash Flow | - | 8.65M | 325.39M | 2.68M | 160.61M |
| Capital Expenditure | - | -124.30K | -89.98K | -538.09K | -164.62K |
| Free Cash Flow | - | -67.29M | -93.14M | -120.67M | -137.24M |
| Net Change in Cash | - | -58.64M | 232.25M | -117.99M | 23.37M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -51.1% | -26.3% | -50.1% | -64.8% |
| ROCE % | - | -58.0% | -25.2% | -54.3% | -62.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 10.04% | 6.57M | $238.78M |
| 2 | General Atlantic, L.P. | 10.02% | 6.55M | $238.25M |
| 3 | Foresite Capital Management IV, LLC | 7.31% | 4.78M | $173.80M |
| 4 | venBio Partners LLC | 7.10% | 4.64M | $168.88M |
| 5 | Viking Global Investors, L.P. | 5.59% | 3.65M | $132.87M |
| 6 | Eqt Fund Management S.a R.l. | 5.24% | 3.42M | $124.55M |
| 7 | Deerfield Management Company, L.P | 5.16% | 3.38M | $122.79M |
| 8 | Bain Capital Life Sciences Investors, LLC | 4.09% | 2.68M | $97.31M |
| 9 | Wellington Management Group, LLP | 3.66% | 2.39M | $87.03M |
| 10 | Polar Capital Holdings PLC | 3.56% | 2.33M | $84.61M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PHVS
$PHVS stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPdXNYYVlxVmpFT05aSk0wZXpsRzR5bE9MZ0FBUHY3VzZvZzVvUjVuSjV4ZGg2dW1PbmhhcGw5Wjd2b0F0QWE1RERMN2N3UnVxYlhlc3RpSnQzdFZOVElFaXR0ejBCY2sxdUNNa1owa2hsTGxLV2RpLVhqZ0E3NnlkMlVobkZXUTRIdEd0YW…
Why Is Pharvaris Stock Soaring Tuesday? - Benzinga
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPN09sVVUyMnBaOE0xSzZIazFHLU4zb2c1UlpFdkNoUGJpUWNWaDlFSjFCVTJ6VkdiODhPQ1FEYXZWU2FTMjI0bFNOdDE3YjFuYnB5M00xUU9ZR3RqczR5TU9uRG1MaDB6X3MxQTBRU0d6YTJpSnN6WFF0REx5WTR1Zkg4VVVHOWtGOXdra1…
PHVS Stock Jumps 17% After Phase 3 Win; 0.35 Monthly Attacks Is the Number That Matters - TechStock²
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOOEVsWnMtSnVNdlZQMGJ1Zy1DU3AyQUhxbzhvMDVPcXFKNlYxamI3cklIQVdKYmdnb05iZFpzYmdYLUo2YnpZUGN0RExtS2o0b2dsNENXajlMUDg1QjdJTUQtR2s2S0xBWExfSUc5cmxhVlM4S3MwU2tfdnlXcXhBTlQ1ZGJYS0lWeDROeH…
Pharvaris posts late-stage trial win for HAE drug (PHVS:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPWVRTSjhRY3NrbTcyR0t4dllfNXFwcWluV3B5WUUwVi1yamVONzJGSkRRUGxYUlBua0dFVi0ybnFyNGRPcDhBRU5uWndTVVdNb29EN0Fxck92Snl4UlpMT1YxVzRxZG10VElPeVhHb200X0YzQWptdGEtUEo5dHdrWGc5RDZEYWdPX0xZ?o…
Rare swelling attacks plunge in Pharvaris (PHVS) pill trial, with key U.S. drug decisions slated for 2027. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQTWx1ekp0aUk1bHhjOERTYmZNQ0VQdURpeFRLdHBQdzZPNDdQU09EUGdZQXRXLXlzQ295QlgyYTZveGVCRWRiN1R3V0J0cTd6MVVaQ1o4aFVCdnphbWdyUUZzY2h4ejZ1a0JjanhrVTB1LW43Yk1scUFUZl9paGY3allta1lRQ2NSOTNBMj…
Pharvaris stock surges 27% on positive trial data - Investing.com
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPc2FsVHE3SDg5R21FM3JQbF8xMEtDaGwtdWpadnR4ckVPX1dvWW5QU0tPVnNtbTNueWZBaTk2M2F3NngyWkxFSkYtZ3pENl9zMTNFdUx5X21iZGtWWHVLQ1lBMXR2QjU5UjNsVlNCSk5Cb05lRDBuSTRfOGNETUtGNlFWWGhYckJZeUd0a0…
PHVS — Frequently Asked Questions
What is the current share price of Pharvaris N.V. (PHVS)?
As of 2026-09-19 21:16 PDT, Pharvaris N.V. (PHVS) trades at $37.84 on NasdaqGS. Its 52-week range is $20.96 to $37.84.
What is the market capitalisation of PHVS?
Pharvaris N.V. (PHVS) has a market capitalisation of $2.66B on NasdaqGS.
What is the P/E ratio of PHVS?
PHVS trades at a trailing price-to-earnings (P/E) ratio of -12.61. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 7.30.
What is the return on equity (ROE) of PHVS?
PHVS has a return on equity (ROE) of -70.46%. Its return on capital employed (ROCE) is -62.47%.
Is PHVS a good stock to buy?
This page provides a data-driven analysis of Pharvaris N.V. (PHVS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.